Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Change in Cash (2016 - 2025)

Ekso Bionics Holdings (EKSO) has disclosed Change in Cash for 13 consecutive years, with -$1.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Cash rose 13.67% to -$1.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$5.3 million, a 148.21% decrease, with the full-year FY2025 number at -$5.3 million, down 148.21% from a year prior.
  • Change in Cash was -$1.6 million for Q4 2025 at Ekso Bionics Holdings, up from -$2.5 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $36.7 million in Q1 2021 to a low of -$8.7 million in Q4 2022.
  • A 5-year average of -$584650.0 and a median of -$2.8 million in 2022 define the central range for Change in Cash.
  • Biggest YoY gain for Change in Cash was 1656.75% in 2021; the steepest drop was 293.87% in 2021.
  • Ekso Bionics Holdings' Change in Cash stood at -$3.0 million in 2021, then plummeted by 185.36% to -$8.7 million in 2022, then skyrocketed by 84.99% to -$1.3 million in 2023, then crashed by 38.49% to -$1.8 million in 2024, then rose by 13.67% to -$1.6 million in 2025.
  • Per Business Quant, the three most recent readings for EKSO's Change in Cash are -$1.6 million (Q4 2025), -$2.5 million (Q3 2025), and -$2.8 million (Q2 2025).